These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28254131)

  • 21. Pancreatic Cancer: A Time to Change.
    Ferrone CR; Ryan DP
    Ann Surg; 2020 Jun; 271(6):1003-1004. PubMed ID: 32398612
    [No Abstract]   [Full Text] [Related]  

  • 22. Vasodilator therapy for heart failure: what have we learned from controlled clinical trials?
    Cohn JN; Rector TS
    JAMA; 1988 Jun; 259(23):3456-7. PubMed ID: 3373685
    [No Abstract]   [Full Text] [Related]  

  • 23. Previous hospitalizations predict both hospital readmissions and mortality in patients with heart failure.
    Tokatli A; Ural D
    Cardiol J; 2016; 23(2):224. PubMed ID: 27145716
    [No Abstract]   [Full Text] [Related]  

  • 24. [Beta receptor blocker for therapy of chronic cardiac insufficiency. A vision of clinical pharmacology].
    Schmidt BM; Wehling M; Ertl G
    Dtsch Med Wochenschr; 1998 Feb; 123(7):171-3. PubMed ID: 9505941
    [No Abstract]   [Full Text] [Related]  

  • 25. How to avoid sudden cardiac death.
    Wan Y; Zou J; Shi Y; Zhang Y; Liu Q
    Eur J Prev Cardiol; 2017 Nov; 24(16):1790. PubMed ID: 28952797
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of carvedilol on survival in severe chronic heart failure. A trial of the beta-blocker bucindolol in patient with advanced heart failure].
    Bosimini E
    Ital Heart J Suppl; 2001 Aug; 2(8):919-21. PubMed ID: 11582729
    [No Abstract]   [Full Text] [Related]  

  • 27. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).
    Zareba W; Piotrowicz K; McNitt S; Moss AJ;
    Am J Cardiol; 2005 Jun; 95(12):1487-91. PubMed ID: 15950580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A global ranking approach to end points in trials of mechanical circulatory support devices.
    Felker GM; Anstrom KJ; Rogers JG
    J Card Fail; 2008 Jun; 14(5):368-72. PubMed ID: 18514927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.
    Packer M
    Circ Heart Fail; 2016 Apr; 9(4):e002837. PubMed ID: 27009552
    [No Abstract]   [Full Text] [Related]  

  • 30. Benefits of DuraHeart™: 'a bridge to life' when treating end-stage heart disease.
    Tsuneyoshi H; Rao V
    Future Cardiol; 2011 Mar; 7(2):133-5. PubMed ID: 21453017
    [No Abstract]   [Full Text] [Related]  

  • 31. Representativeness of Participants in Heart Failure E-Health Trials: A Report From the E-Vita HF Study.
    Wagenaar KP; Hakim N; Broekhuizen BD; Jaarsma T; Rutten FH; Hoes AW
    J Card Fail; 2017 Jan; 23(1):88-89. PubMed ID: 27565046
    [No Abstract]   [Full Text] [Related]  

  • 32. Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure.
    Zannad F; Stough WG; Mahfoud F; Bakris GL; Kjeldsen SE; Kieval RS; Haller H; Yared N; De Ferrari GM; Piña IL; Stein K; Azizi M
    Hypertension; 2015 Jan; 65(1):5-15. PubMed ID: 25350982
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical Decision Support for Heart Failure Referral-More Work, Better Outcomes?
    Vader JM; La Rue SJ
    J Card Fail; 2017 Oct; 23(10):727-728. PubMed ID: 28842381
    [No Abstract]   [Full Text] [Related]  

  • 34. Heart Failure "End Result Cards": Solid B.
    O'Connor CM
    JACC Heart Fail; 2015 Dec; 3(12):1001-2. PubMed ID: 26671677
    [No Abstract]   [Full Text] [Related]  

  • 35. Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients.
    Krishnamoorthy A; Tonks RW; Adams PA; Felker GM; Patel CB; Mentz RJ
    J Card Fail; 2015 Jul; 21(7):608-9. PubMed ID: 25921523
    [No Abstract]   [Full Text] [Related]  

  • 36. [Rosuvastatin has no effect on clinical outcomes in patients with heart failure. Results of the GISSI-HF trial].
    Preorazhenskiĭ DV
    Kardiologiia; 2009; 49(4):64-5. PubMed ID: 19463122
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardiac resynchronization therapy: a new frontier in the management of heart failure.
    Gurevitz O; Glikson M
    Isr Med Assoc J; 2003 Aug; 5(8):571-5. PubMed ID: 12929296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac resynchronization therapy for heart failure shows great promise.
    Ovsyshcher IE; Auricchio A
    Isr Med Assoc J; 2003 Aug; 5(8):589-91. PubMed ID: 12929300
    [No Abstract]   [Full Text] [Related]  

  • 40. Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management).
    Stehlik J; Estep JD; Selzman CH; Rogers JG; Spertus JA; Shah KB; Chuang J; Farrar DJ; Starling RC;
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.